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Abstract
Background: Tetanus is a serious but vaccine-preventable disease and fatality rate of the disease
is high in the neonates and the elderly. The aim of this study was to detect the tetanus antibody
prevalence in the over sixty-year age residents of the nursing homes in Bolu.
Methods: A voluntary-based study was done in the residents of two nursing homes in Bolu,
Turkey. Blood samples were taken from 71 volunteers residing in there nursing homes. Tetanus
IgG antibodies were measured by a commercial ELISA kit.
Results: Among overall subjects, only 11 (15.7 %) had the protective tetanus antibody titers at the
time of the study. Totally, 10 subjects were examined in emergency rooms due to trauma or
accidents within the last ten years and, four (40%) of them had protective antibody levels. Of the
remaining 61 subjects only 7 (11%) had protective antibody levels (p < 0.05) [Relative Risk = 3.49,
95% Confidence Interval 1.24–9.77].
Conclusions: Tetanus antibody level is below the protective level in the majority of the over-
sixty-year-age subjects residing in the nursing homes. Each over sixty-year age person in our
country should be vaccinated. Until this is accomplished, at least, nursing home residents should be
vaccinated during registration.
Background
Tetanus is an acute disease caused by the tetanus toxin,
released by the bacterium Clostridium tetani. Tetanus
spores are present in soil and manure and may be intro-
duced into the body through a puncture wound, burn or
scratch. Tetanus can never be eradicated because the
spores are widely spread in the environment, and found
in the intestinal flora of domestic animals, horses, chick-
ens, and humans. Tetanus is not spread from person to
person [1].
Tetanus is preventable by proper immunization. How-
ever, the disease is still prevalent even in the most devel-
oped countries and it often emerges in the elderly [2]. The
prevalence of neonatal tetanus is considered a criterion for
developmental level of the country. Every year, the cases
of neonatal tetanus are reported in four to six European
countries; Turkey and Albania have the highest occurrence
rates [3].
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the elderly patients [4]. Age-related mortality rates were
found to be 79.4 % in the neonatal period [5], 11 % in
adults younger than 50 years old and 54 % in adults older
than 50 years old [4,6]. Totally, 280 cases were observed
in Turkey between 1994 and 1995. The mortality rate was
29.8% for these cases [7]. Risk is greater in people over 60,
particularly in the developed countries [8].
In the USA, the disease occurs at a six-times higher rate in
this age group [8,9]. Of 99 tetanus patients whose com-
plete information was reported to the Centers for Disease
Control and Prevention (CDC) during 1987 and 1988,
68% were over 50, while only six were younger than 20.
No cases of neonatal tetanus were reported. The disease
continues to occur almost exclusively among people who
are unvaccinated or inadequately vaccinated or whose
vaccination histories are unknown or uncertain [10].
Bolu is a city in the Western Black Sea Region of Turkey
and has a population of approximately 283.000. There are
two nursing homes (Izzet Baysal and Neziha Baysal Nurs-
ing Homes) in the each with a boarding capacity of 60
people. Tetanus antibody level in such a specific group has
not been researched in the country yet. The purpose of this
study was to detect tetanus antibody prevalence in the vol-
untary residents of the nursing homes over 60 years old.
Methods
This study was performed May 1–30, 2004. Subjects were
selected from Izzet Baysal and Neziha Baysal Nursing
home residents who volunteered for antibody
measurement.
A standard form was filled including subjects' clinical
information, demographic traits along with vaccination
and injury stories. 10 cc venous blood was taken from
each subject and kept at -20°C until the day of study.
Tetanus Ig G antibodies were measured by a commercial
ELISA kit [Novatec Dietzenbach, Germany] at a 450/620
nm wavelength. The results were evaluated in the way pre-
viously defined by Schoroder et al. [11]. Briefly, antitoxin
levels below 0.1 IU/L were defined as "below protective
level" and antitoxin levels above 0.1 IU/L were defined as
"at protective level".
Students't-test was used to compare quantitative variables
while chi-square and Fischer's exact tests (two-tailed) were
used for qualitative data, p < 0.05 was considered to be
significant. Statistical analyses were performed with Epi-
info 6.0 (Center for Disease Control, Atlanta, USA).
Results
Subjects
We aimed to include all residents of the nursing homes. In
the study period, 78 subjects were staying in the two nurs-
ing homes (40 residents in Izzet Baysal Nursing Home
and 38 residents in Neziha Baysal Nursing Home). How-
ever, 7 subjects did not want to participate in the study.
Therefore, these seven subjects could not be included.
Antibody results and properties of subjects
A total of 71 voluntary subjects [54 (76%) male and 17
(24%) female] were included in the study. The mean age
was 71. Only 11 (15.4%) of the 71 subjects had a protec-
tive antibody level against tetanus. 15 subjects were aged
between 60–65 (3 of them had protective antibodies), 22
subjects were aged between 66–75 (2 of them had protec-
tive antibodies) and 34 of 71 subjects were aged ≥ 76 years
(6 of them had protective antibodies). Protective antibody
level decreased with every age group (60–65, 66–75, and
≥ 76) above 60 years old, but there were no statistically
significant difference between the five-year age periods
above 60 (p > 0.05) (Fig. 1).
Totally, 10 subjects were examined in emergency rooms
due to trauma or accidents within the last ten years. While
four (40%) of them had protective antibody levels, only 7
(11%) of 61 subjects who didn't get examined in the
emergency room had protective antibody levels (p < 0.05)
[Relative Risk = 3.49, 95% Confidence Interval 1.24–
9.77].
Only 10 (14%) of the 71 subjects had been vaccinated in
the last ten years. Five of them had been vaccinated as a
Antibody levels of subjectsFigure 1
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demographic properties of subjects were presented in the
Table 1.
Discussion
According to the records of the Ministry of Health, 2039
tetanus cases were detected in Turkey between 1980–
2002, 462 (23%) of which died [12]. In our country, a
vaccination campaign against tetanus was initiated in the
mid 1960s. However, it was carried out irregularly until
1985. After 1985, 3 doses of tetanus toxoid were given to
all neonates after birth and a booster dose was applied in
the 16th month followed by vaccination of primary
school children at aged 7 and 12. While 67 neonatal teta-
nus cases were detected in 1990 in a population of
57.582.244, 32 neonatal tetanus cases were detected in
2002 in a population of 70.415.244 [12]. The neonatal
tetanus rate has decreased with an increased rate vaccina-
tion in the country. In Turkey, females are vaccinated dur-
ing pregnancy and males are vaccinated during military
service but there is no vaccination program for the elderly.
Unfortunately, a falling could not be achieved in the
prevalence of tetanus in the elderly. Similar results were
obtained in the developed countries, too. For instance, it
was established that, rate of occurrence of tetanus in the
people older than 60 was ten times higher than the young
in Italy [9]. Routine vaccination programs focus on the
childhood period in the developing countries. However,
according to researches, the majority of adult population
is sensitive to tetanus [13].
In our study group, only 11 (15.4%) of 71 subjects had
protective antibody levels while the rest were under the
risk of tetanus. This resultsuggested that lack of protective
immunity among nursing home residents was a signifi-
cant public health concern. In industrialized countries tet-
anus has become a rare disease and an infrequent cause of
death, mainly due to the implementation of comprehen-
sive immunization programs. But, tetanus is still an
important problem for the developing countries, due to
poor immunization standards and inadequate hygiene
[14]. Deaths due to tetanus in Turkey mostly occur in the
elderly. The 27.4 % of the total deaths caused by tetanus
in 1989 occurred in the patients over 40. But today mor-
tality rate in this age group ranges between 48.8–60.6%
[15]. Those who are not vaccinated and the elderly are at
risk [16].
Individuals over 60 are usually retired people and spend-
ing most of their time in garden or land-work. Tetanus
spores may be introduced into the body through a punc-
ture wound, scratch during these works. So they face risk
of getting tetanus. Also, 28 % of our subjects still were
busy with soil and garden work.
According to our results, antibody levels in individuals
who had been examined in an emergency room within
the last ten years due to injury are significantly higher than
who didn't have such a history (p < 0.05). This situation
suggests that vaccination programs are not well estab-
lished in countries like Turkey, thus injuries and accidents
expose people over 60 to a great risk of getting the tetanus
prophylaxis [17].
Once the existence of tetanus is suspected, intensive, and
effective management is essential. The patient should
receive intensive care aimed at prevention of muscle
spasms, prevention of respiratory tract and metabolic
complications, and neutralization of circulating toxins
[18]. Assuming that one tetanus case stays in the intensive
care unit for at least fifteen days, it costs $9.000 per case
approximately. In Turkey, 30.000 people can be vacci-
nated with a booster dose of tetanus vaccine for this
amount of money [19,20]. Moreover, vaccination will not
only ensure economic benefits but also protect thousands
of people against tetanus. Apart from being more profita-
ble, such policy will improve the health statistics of the
country [20]. It is imperative that every person over 60
should be vaccinated against tetanus.
Conclusions
The lack of protective immunity against tetanus among
the nursing home residents is a significant public health
concern. A vaccination program including every individ-
Table 1: Demographic characteristics and antibody levels of subjects according to age groups
Characteristics TOTAL n = 71 (%)
Age (mean ± SD) 71.1 ± 8.6
Female/Male 17/54
Diabetes mellitus 7 (9.8)
Emergency room visits due to injury within the last 10 years 10 (14)
Tetanus vaccine within last 10 years Emergency room visit/No emergency room visit 5 (7)/5 (7)
Occupation with soil / garden-work 20 (28.1)
Average tetanus Ig G level 0.080
Tetanus Ig G >0.1 IU/ml 11 (15.4)Page 3 of 4
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ual over 60 should be charted immediately. After the pri-
mary series of 3 doses, protection against tetanus should
be sustained by scheduling booster doses routinely in
every 10 years [21]. Until this campaign is accomplished,
at least, nursing home residents should be vaccinated dur-
ing registration.
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